The Clorox Company (NYSE:CLX) Shares Sold by Confluence Investment Management LLC

Confluence Investment Management LLC reduced its position in The Clorox Company (NYSE:CLX - Free Report) by 2.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 840,746 shares of the company's stock after selling 19,643 shares during the quarter. Clorox makes up about 1.8% of Confluence Investment Management LLC's holdings, making the stock its 17th largest position. Confluence Investment Management LLC owned about 0.68% of Clorox worth $123,800,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of CLX. Wellington Management Group LLP lifted its stake in shares of Clorox by 18.8% during the 4th quarter. Wellington Management Group LLP now owns 4,074 shares of the company's stock valued at $662,000 after buying an additional 646 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Clorox by 7.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 49,141 shares of the company's stock valued at $7,981,000 after buying an additional 3,364 shares in the last quarter. Capstone Triton Financial Group LLC lifted its stake in shares of Clorox by 4.5% during the 4th quarter. Capstone Triton Financial Group LLC now owns 6,213 shares of the company's stock valued at $1,009,000 after buying an additional 268 shares in the last quarter. Wood Tarver Financial Group LLC purchased a new stake in shares of Clorox during the 4th quarter valued at approximately $31,000. Finally, Smith Shellnut Wilson LLC ADV lifted its stake in Clorox by 3.0% in the 4th quarter. Smith Shellnut Wilson LLC ADV now owns 4,375 shares of the company's stock worth $711,000 after purchasing an additional 127 shares in the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Pierre R. Breber acquired 4,000 shares of the stock in a transaction on Wednesday, May 7th. The stock was bought at an average cost of $136.57 per share, with a total value of $546,280.00. Following the transaction, the director now directly owns 4,000 shares in the company, valued at approximately $546,280. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.57% of the stock is owned by insiders.

Clorox Stock Down 1.6%

NYSE:CLX traded down $2.08 during mid-day trading on Monday, hitting $129.80. 483,967 shares of the company's stock were exchanged, compared to its average volume of 1,338,622. The business has a fifty day moving average price of $138.30 and a 200 day moving average price of $151.04. The company has a market cap of $16.00 billion, a PE ratio of 35.48, a P/E/G ratio of 2.62 and a beta of 0.60. The Clorox Company has a one year low of $129.19 and a one year high of $171.37. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60.

Clorox (NYSE:CLX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The business had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The firm's quarterly revenue was down 8.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.71 earnings per share. Equities analysts predict that The Clorox Company will post 7.15 EPS for the current year.

Wall Street Analyst Weigh In

CLX has been the topic of several recent analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Evercore ISI set a $140.00 price objective on Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. Morgan Stanley dropped their price objective on Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Barclays dropped their price objective on Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research note on Wednesday, May 7th. Finally, Wells Fargo & Company dropped their price objective on Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $151.23.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.